SG11201909457XA - Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 - Google Patents
Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1Info
- Publication number
- SG11201909457XA SG11201909457XA SG11201909457XA SG11201909457XA SG 11201909457X A SG11201909457X A SG 11201909457XA SG 11201909457X A SG11201909457X A SG 11201909457XA SG 11201909457X A SG11201909457X A SG 11201909457XA
- Authority
- SG
- Singapore
- Prior art keywords
- tarrytown
- new york
- international
- rule
- saw mill
- Prior art date
Links
- 108700028369 Alleles Proteins 0.000 title abstract 3
- 208000019693 Lung disease Diseases 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 102100033500 Interleukin-33 Human genes 0.000 abstract 3
- 108010067003 Interleukin-33 Proteins 0.000 abstract 3
- 102000045959 Interleukin-1 Receptor-Like 1 Human genes 0.000 abstract 2
- 108700003107 Interleukin-1 Receptor-Like 1 Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 230000002327 eosinophilic effect Effects 0.000 abstract 2
- 208000030853 Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000000592 Nasal Polyps Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485077P | 2017-04-13 | 2017-04-13 | |
| PCT/US2018/023266 WO2018190990A1 (en) | 2017-04-13 | 2018-03-20 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909457XA true SG11201909457XA (en) | 2019-11-28 |
Family
ID=61911717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909457X SG11201909457XA (en) | 2017-04-13 | 2018-03-20 | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11708415B2 (ko) |
| EP (2) | EP3957752A3 (ko) |
| JP (2) | JP7321939B2 (ko) |
| KR (2) | KR20230164197A (ko) |
| CN (1) | CN110431240A (ko) |
| AU (1) | AU2018252974A1 (ko) |
| CA (1) | CA3059350A1 (ko) |
| MX (1) | MX2019012171A (ko) |
| SG (1) | SG11201909457XA (ko) |
| WO (1) | WO2018190990A1 (ko) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110997725A (zh) | 2017-06-12 | 2020-04-10 | 蓝鳍生物医药公司 | 抗-il1rap抗体和抗体药物缀合物 |
| JP7165618B2 (ja) * | 2019-04-23 | 2022-11-04 | ジェネシスヘルスケア株式会社 | アレルギー性鼻炎のリスクを判定する方法 |
| US20230272096A1 (en) * | 2021-11-11 | 2023-08-31 | Regeneron Pharmaceuticals, Inc. | Treatment Of Lung Disease Based Upon Stratification Of Polygenic Risk Score For Interleukin 33 (IL-33) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| ES2382891T3 (es) | 2000-05-26 | 2012-06-14 | Immunex Corporation | Uso de anticuerpos IL-4R y sus composiciones |
| ES2383809T3 (es) | 2003-11-07 | 2012-06-26 | Immunex Corporation | Anticuerpos que se unen al receptor de interleucina 4 |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| CN101426518A (zh) * | 2006-01-11 | 2009-05-06 | 艾罗文斯公司 | 用于治疗人类和非-人类灵长类中哮喘的方法和组合物 |
| CN1896275B (zh) * | 2006-06-29 | 2010-04-07 | 四川大学华西医院 | 一种检测与慢性阻塞性肺部疾病相关的snp的pcr试剂盒 |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| EP2069403B1 (en) | 2006-10-02 | 2014-05-07 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| WO2010067381A1 (en) * | 2008-12-12 | 2010-06-17 | Decode Genetics Ehf | Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction |
| WO2011031600A1 (en) | 2009-09-10 | 2011-03-17 | Schering Corporation | Use of il-33 antagonists to treat fibrotic disease |
| RU2597288C2 (ru) | 2011-02-23 | 2016-09-10 | Ф. Хоффманн-Ля Рош Аг | Антитела против человеческого il33r и их применение |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| JO3623B1 (ar) | 2012-05-18 | 2020-08-27 | Amgen Inc | البروتينات المرتبطة بمولد المستضاد st2 |
| WO2014031610A1 (en) | 2012-08-21 | 2014-02-27 | Sanofi | Methods for treating or preventing asthma by administering an il-4r antagonist |
| US10703799B2 (en) * | 2012-12-10 | 2020-07-07 | Vib Vzw | IL-33R and IL-1RAcP fusion proteins |
| JO3532B1 (ar) * | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| CA2904377C (en) | 2013-03-15 | 2021-07-13 | Regeneron Pharmaceuticals, Inc. | Il-33 antagonists and uses thereof |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| BR112016013347B1 (pt) | 2013-12-26 | 2023-12-12 | Mitsubishi Tanabe Pharma Corporation | Anticorpo monoclonal humano neutralizante anti-il-33, composição farmacêutica, inibidor da expressão de citocinas, molécula de ácido nucleico, vetor, célula bacteriana transgênica, método de produção e uso dos mesmos |
| SG10201805934RA (en) | 2014-01-10 | 2018-08-30 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| CA2940295A1 (en) * | 2014-02-21 | 2015-08-27 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| NO2785538T3 (ko) | 2014-05-07 | 2018-08-04 | ||
| JP6929771B2 (ja) | 2014-11-10 | 2021-09-01 | ジェネンテック， インコーポレイテッド | 抗インターロイキン−３３抗体及びその使用 |
| JP7231326B2 (ja) | 2014-11-10 | 2023-03-01 | ジェネンテック， インコーポレイテッド | Ｉｌ－３３媒介性障害のための治療及び診断方法 |
| CA2967602A1 (en) * | 2014-11-14 | 2016-05-19 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| CN104531689A (zh) * | 2014-12-12 | 2015-04-22 | 上海交通大学医学院附属新华医院 | 与哮喘相关的基因单核苷酸多态性位点、预测哮喘的试剂盒及其应用 |
| JP6862351B2 (ja) | 2015-03-31 | 2021-04-21 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 新規ｉｌ３３型、変異型のｉｌ３３、抗体、アッセイ及びそれらの使用方法 |
| EA201890891A1 (ru) * | 2015-10-06 | 2018-09-28 | Ридженерон Фармасьютикалз, Инк. | Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение |
| TW202332696A (zh) | 2016-12-01 | 2023-08-16 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
-
2018
- 2018-03-20 KR KR1020237039438A patent/KR20230164197A/ko not_active Application Discontinuation
- 2018-03-20 SG SG11201909457X patent/SG11201909457XA/en unknown
- 2018-03-20 KR KR1020197030870A patent/KR102605045B1/ko active IP Right Grant
- 2018-03-20 MX MX2019012171A patent/MX2019012171A/es unknown
- 2018-03-20 CN CN201880018649.2A patent/CN110431240A/zh active Pending
- 2018-03-20 CA CA3059350A patent/CA3059350A1/en active Pending
- 2018-03-20 EP EP21162316.0A patent/EP3957752A3/en active Pending
- 2018-03-20 EP EP18716446.2A patent/EP3610041A1/en not_active Withdrawn
- 2018-03-20 JP JP2019555834A patent/JP7321939B2/ja active Active
- 2018-03-20 WO PCT/US2018/023266 patent/WO2018190990A1/en unknown
- 2018-03-20 AU AU2018252974A patent/AU2018252974A1/en active Pending
-
2019
- 2019-10-11 US US16/599,709 patent/US11708415B2/en active Active
-
2023
- 2023-06-07 US US18/330,736 patent/US20230374145A1/en active Pending
- 2023-07-26 JP JP2023121229A patent/JP2023129607A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3957752A3 (en) | 2022-06-15 |
| EP3610041A1 (en) | 2020-02-19 |
| US20200031922A1 (en) | 2020-01-30 |
| JP2020516289A (ja) | 2020-06-11 |
| EP3957752A2 (en) | 2022-02-23 |
| JP2023129607A (ja) | 2023-09-14 |
| WO2018190990A1 (en) | 2018-10-18 |
| US11708415B2 (en) | 2023-07-25 |
| MX2019012171A (es) | 2019-11-25 |
| KR102605045B1 (ko) | 2023-11-27 |
| RU2019136253A (ru) | 2021-05-13 |
| US20230374145A1 (en) | 2023-11-23 |
| RU2019136253A3 (ko) | 2021-12-17 |
| KR20190140928A (ko) | 2019-12-20 |
| CN110431240A (zh) | 2019-11-08 |
| KR20230164197A (ko) | 2023-12-01 |
| AU2018252974A1 (en) | 2019-11-28 |
| CA3059350A1 (en) | 2018-10-18 |
| JP7321939B2 (ja) | 2023-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201807785VA (en) | Neuroactive steroids, compositions, and uses thereof | |
| SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201805579SA (en) | Recombinant igg fc multimers | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201909457XA (en) | Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1 | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201804057TA (en) | An actuator housing for a metered dose inhaler device | |
| SG11201808829VA (en) | Tdp-43 mitochondrial localization inhibitor for the treatment of neurodegenerative disease | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201901305YA (en) | Mice comprising mutations resulting in expression of c-truncated fibrillin-1 |